Sunesis Pharmaceuticals

US: SNSS

$31.9m market cap

$0.53 last close

Sunesis Pharmaceuticals is a pharmaceutical company focused on oncology. The company has developed vecabrutinib, a BTK inhibitor for CLL for Imbruvica refractory patients currently in Phase I/II.

Investment summary

In January 2019 Sunesis announced that its Phase Ib/II study of vecabrutinib for B-cell cancers advanced to the 100mg cohort. The company experienced a series of unavoidable clinical delays in the 50mg arm but was eventually able expand the number of clinical sites and overenroll the cohort. The 100mg dose is the first that is expected to potentially provide indications of efficacy and Sunesis will provide a clinical update in Q219.

Y/E Dec
Revenue (US$m)
EBITDA (US$m)
PBT (US$m)
EPS (c)
P/E (x)
P/CF (x)
2016A 2.5 (36.3) (38.0) (242.37) N/A N/A
2017A 0.7 (34.4) (35.5) (144.63) N/A N/A
2018E 0.2 (27.5) (28.3) (79.53) N/A N/A
2019E 0.0 (30.4) (31.1) (48.97) N/A N/A
Last updated on 15/02/2019
Industry outlook

Sunesis is an oncology company with an early stage asset with a validated target targeting patients that are in B-cell malignancies.

Last updated on 15/02/2019
Sector
Healthcare
Share price graph
Balance sheet
Forecast net cash (US$m) 5.8
Forecast gearing ratio (%) N/A
Price performance
%
1m
3m
12m
Actual (22.1) (57.7) (91.2)
Relative* (26.8) (58.4) (91.4)
52-week high/low US$7.4/US$0.2
*% relative to local index
Key management
William Quinn Chief Financial Officer and Senior Vice Presi